Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies
about
Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentA categorical structure-activity relationship analysis of GPR119 ligands.Commensal bacteria make GPCR ligands that mimic human signalling molecules.Therapeutic application of GPR119 ligands in metabolic disorders.A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.Investigational insulin secretagogues for type 2 diabetes.YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model.Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study.The current state of GPCR-based drug discovery to treat metabolic disease.β-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation.Gut Microbiota Dysbiosis Drives and Implies Novel Therapeutic Strategies for Diabetes Mellitus and Related Metabolic Diseases.Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus.GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16
P2860
Q26830274-FE89F041-3E6F-49EA-A0C9-37ADCC3896B6Q27311495-7F39391D-E59A-44C0-9819-0CFC85696447Q38635610-874E4F03-84AA-4EAE-9A0F-B247321F6840Q38655382-BD606283-0B22-4B86-B8F8-FE16F4EA12F3Q38707493-2D3157C6-81C5-452E-A930-4C493B9C064BQ38735419-DB38731F-10E3-46D4-A72B-D89BBD18668BQ38737053-20D3ED79-CEBD-4795-943F-833E1AF42F3CQ42699213-14679858-69E9-4AAE-BF13-D340CD222A12Q47696468-92483C2F-9359-4EEF-8842-2C6A54991F82Q48170686-3BA4456B-1775-4099-B88E-9AEFA2C8A586Q49769640-9A06C4D2-B7E7-43B2-9CE8-0E2226DC534EQ51246350-0526B529-B1BE-44CD-884B-4A4E69B8343EQ52679204-6413F508-8AC0-40CD-A248-069EF107A27EQ53206867-D96A655D-F32B-4250-8A4E-99859A323DB2Q57072608-EA2B3138-2065-456E-BBC8-034CDA1F428F
P2860
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Gut hormone pharmacology of a ...... ts from two randomized studies
@ast
Gut hormone pharmacology of a ...... ts from two randomized studies
@en
Gut hormone pharmacology of a ...... ts from two randomized studies
@nl
type
label
Gut hormone pharmacology of a ...... ts from two randomized studies
@ast
Gut hormone pharmacology of a ...... ts from two randomized studies
@en
Gut hormone pharmacology of a ...... ts from two randomized studies
@nl
prefLabel
Gut hormone pharmacology of a ...... ts from two randomized studies
@ast
Gut hormone pharmacology of a ...... ts from two randomized studies
@en
Gut hormone pharmacology of a ...... ts from two randomized studies
@nl
P2093
P2860
P921
P1433
P1476
Gut hormone pharmacology of a ...... ts from two randomized studies
@en
P2093
David A Collins
Dawn Gillmor
Derek J Nunez
George Atiee
Glen Apseloff
Leonor Corsino
Linda Morrow
Mark A Bush
Paul L Feldman
Susan L McMullen
P2860
P304
P356
10.1371/JOURNAL.PONE.0092494
P407
P577
2014-01-01T00:00:00Z